HRP20100363T1 - Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom - Google Patents
Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom Download PDFInfo
- Publication number
- HRP20100363T1 HRP20100363T1 HR20100363T HRP20100363T HRP20100363T1 HR P20100363 T1 HRP20100363 T1 HR P20100363T1 HR 20100363 T HR20100363 T HR 20100363T HR P20100363 T HRP20100363 T HR P20100363T HR P20100363 T1 HRP20100363 T1 HR P20100363T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- combination
- diarrhea
- treatment
- combination according
- Prior art date
Links
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 title claims 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 title claims 3
- ODUOJXZPIYUATO-UHFFFAOYSA-N 2-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]acetic acid (phenylmethyl) ester Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 title 1
- ODUOJXZPIYUATO-IBGZPJMESA-N benzyl 2-[[(2r)-2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate Chemical compound C([C@@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-IBGZPJMESA-N 0.000 title 1
- 108700010883 dexecadotril Proteins 0.000 title 1
- 229950008996 dexecadotril Drugs 0.000 title 1
- 108700040249 racecadotril Proteins 0.000 title 1
- 229960002281 racecadotril Drugs 0.000 title 1
- 206010012735 Diarrhoea Diseases 0.000 claims abstract 8
- 208000005577 Gastroenteritis Diseases 0.000 claims abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 19
- 230000037396 body weight Effects 0.000 claims 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 3
- 208000012873 acute gastroenteritis Diseases 0.000 claims 3
- 229960005343 ondansetron Drugs 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 2
- 201000009840 acute diarrhea Diseases 0.000 claims 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 2
- 229960003727 granisetron Drugs 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940122586 Enkephalinase inhibitor Drugs 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940125683 antiemetic agent Drugs 0.000 abstract 1
- 239000002792 enkephalinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290384A EP1563848A1 (en) | 2004-02-12 | 2004-02-12 | New combinations of an anti-emetic agent and an enkephalinase inhibitor |
| PCT/IB2005/000351 WO2005079850A1 (en) | 2004-02-12 | 2005-02-14 | New combinations of an anti emetic agent and an enkephalinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100363T1 true HRP20100363T1 (hr) | 2010-07-31 |
Family
ID=34684783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100363T HRP20100363T1 (hr) | 2004-02-12 | 2010-06-29 | Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8222294B2 (ru) |
| EP (2) | EP1563848A1 (ru) |
| JP (1) | JP4987487B2 (ru) |
| KR (1) | KR101152308B1 (ru) |
| CN (1) | CN1917903B (ru) |
| AT (1) | ATE468138T1 (ru) |
| AU (1) | AU2005215262B2 (ru) |
| BR (1) | BRPI0506631B8 (ru) |
| CA (1) | CA2553827C (ru) |
| CY (1) | CY1110202T1 (ru) |
| DE (1) | DE602005021317D1 (ru) |
| DK (1) | DK1718337T3 (ru) |
| EA (1) | EA010625B1 (ru) |
| EC (1) | ECSP066758A (ru) |
| ES (1) | ES2344909T3 (ru) |
| HR (1) | HRP20100363T1 (ru) |
| MA (1) | MA28354A1 (ru) |
| ME (1) | ME01175B (ru) |
| NO (1) | NO337320B1 (ru) |
| NZ (1) | NZ548635A (ru) |
| PL (1) | PL1718337T3 (ru) |
| PT (1) | PT1718337E (ru) |
| RS (1) | RS51329B (ru) |
| SI (1) | SI1718337T1 (ru) |
| TN (1) | TNSN06246A1 (ru) |
| UA (1) | UA88156C2 (ru) |
| WO (1) | WO2005079850A1 (ru) |
| ZA (1) | ZA200605872B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2900823B1 (fr) | 2006-05-15 | 2009-02-13 | Bioprojet Soc Civ Ile | Nouvelle forme d'administration du racecadotril. |
| EP2462922A1 (en) * | 2010-12-10 | 2012-06-13 | Bioprojet | New form of administration of enkephalinase inhibitor |
| US9801819B2 (en) * | 2012-06-28 | 2017-10-31 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
| PT2866802T (pt) * | 2012-06-28 | 2016-09-05 | Johnson & Johnson Consumer Inc | Composições líquidas racecadotril |
| US9114171B2 (en) * | 2012-06-28 | 2015-08-25 | Mcneil-Ppc, Inc. | Racecadotril liquid compositions |
| RU2632441C2 (ru) | 2012-06-28 | 2017-10-04 | МакНЕЙЛ-ППС, ИНК. | Липидные композиции рацекадотрила |
| MA40859A (fr) | 2014-10-29 | 2017-09-05 | Johnson & Johnson Consumer Inc | Particules de cadotril |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028575D0 (en) * | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
-
2004
- 2004-02-12 EP EP04290384A patent/EP1563848A1/en not_active Withdrawn
-
2005
- 2005-02-14 EA EA200601466A patent/EA010625B1/ru not_active IP Right Cessation
- 2005-02-14 DE DE602005021317T patent/DE602005021317D1/de active Active
- 2005-02-14 NZ NZ548635A patent/NZ548635A/en not_active IP Right Cessation
- 2005-02-14 SI SI200531056T patent/SI1718337T1/sl unknown
- 2005-02-14 AT AT05702484T patent/ATE468138T1/de active
- 2005-02-14 UA UAA200608901A patent/UA88156C2/ru unknown
- 2005-02-14 BR BRPI0506631A patent/BRPI0506631B8/pt not_active IP Right Cessation
- 2005-02-14 CA CA2553827A patent/CA2553827C/en not_active Expired - Fee Related
- 2005-02-14 PT PT05702484T patent/PT1718337E/pt unknown
- 2005-02-14 JP JP2006552718A patent/JP4987487B2/ja not_active Expired - Fee Related
- 2005-02-14 KR KR1020067016159A patent/KR101152308B1/ko active IP Right Grant
- 2005-02-14 DK DK05702484.6T patent/DK1718337T3/da active
- 2005-02-14 AU AU2005215262A patent/AU2005215262B2/en not_active Ceased
- 2005-02-14 ES ES05702484T patent/ES2344909T3/es active Active
- 2005-02-14 US US10/587,899 patent/US8222294B2/en not_active Expired - Fee Related
- 2005-02-14 EP EP05702484A patent/EP1718337B1/en active Active
- 2005-02-14 ME MEP-2010-168A patent/ME01175B/me unknown
- 2005-02-14 PL PL05702484T patent/PL1718337T3/pl unknown
- 2005-02-14 RS RSP-2010/0286A patent/RS51329B/en unknown
- 2005-02-14 CN CN2005800046292A patent/CN1917903B/zh not_active Expired - Fee Related
- 2005-02-14 WO PCT/IB2005/000351 patent/WO2005079850A1/en active Application Filing
-
2006
- 2006-07-17 ZA ZA2006/05872A patent/ZA200605872B/en unknown
- 2006-08-03 TN TNP2006000246A patent/TNSN06246A1/fr unknown
- 2006-08-08 EC EC2006006758A patent/ECSP066758A/es unknown
- 2006-08-10 MA MA29256A patent/MA28354A1/fr unknown
- 2006-09-05 NO NO20063973A patent/NO337320B1/no not_active IP Right Cessation
-
2010
- 2010-06-29 HR HR20100363T patent/HRP20100363T1/hr unknown
- 2010-07-09 CY CY20101100645T patent/CY1110202T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100363T1 (hr) | Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom | |
| BRPI0309142C1 (pt) | suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral | |
| AR045076A1 (es) | Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| AR059324A2 (es) | Una forma solida de dosificacion oral | |
| MX2010008234A (es) | Nueva dosificacion y formulacion. | |
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| JP2009525343A5 (ru) | ||
| SV2002000250A (es) | Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb | |
| MY177027A (en) | Novel dosage and formulation | |
| SI2729130T1 (en) | Combined formulations of darunavir | |
| RU2010147287A (ru) | Комбинированная композиция | |
| AR098745A2 (es) | Composición, kit y uso de compuestos quimioterapéuticos | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| BRPI0418275A (pt) | formulações em multipartìculas para distribuição oral | |
| JP2007522202A5 (ru) | ||
| AR012480A1 (es) | Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| TR200101928T2 (tr) | Geliştirilmiş kararlılığa sahip bileşimler | |
| BRPI0715756B8 (pt) | composição farmacêutica para administração oral, seus usos, e medicamento | |
| UY26176A1 (es) | Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas. | |
| UY24297A1 (es) | Nuevo procedimiento para la formulación de fármacos | |
| HRP20200916T1 (hr) | Uporaba inhibitora aktivnosti ili funkcije pi3k za liječenje primarnog sjörgen-ovog sindroma |